Reaction

Hepatitis E reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,549 reports · 52 co-occurring drugs

As of the last recalculation, Hepatitis E appears in 1,549 FAERS reports alongside 52 co-occurring drug terms. The strongest observed disproportionality signal is EVEROLIMUS TABLETS (PRR 61.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Everolimus Tablets	73	61.3	61.6
Mycophenilic Acid	86	59.0	59.2
Tacrolimus Ointment 0.1%	401	58.0	58.2
Tacrolimus Extended-Release Capsules	401	57.9	58.1
Basiliximab	40	46.9	47.0
Tacrolimus	404	46.5	46.7
Ribavirin	187	44.3	44.4
Mycophenolic Acid	94	41.9	42.1
Prednisolone	378	36.9	37.0
Prednisolone Oral	378	36.9	37.0
Prednisolone Oral Solution	378	36.9	37.0
Mycophenolate Mofetil	301	36.7	36.8
Mycophenolate Mofetil Hydrochloride	301	36.7	36.7
Bendamustine Hcl	36	31.9	32.0
Sirolimus	26	26.4	26.4
Melphalan	41	24.9	24.9
Mesna Injection	14	23.0	23.0
Melphalan Hydrochloride	41	22.5	22.6
Mesna	14	22.5	22.6
Everolimus	74	20.5	20.5
Ifosfamide	27	17.2	17.2
Sofosbuvir	23	15.9	15.9
Fludarabine Phosphate	45	15.8	15.8
Bendamustine Hydrochloride	13	14.7	14.7
Rituximab	201	14.5	14.5
Cyclophosphamide Injection, Solution	160	13.4	13.4
Cyclophosphamide	160	13.4	13.4
Cyclophosphamide For Injection	160	13.4	13.4
Baricitinib	9	12.6	12.6
Lamivudine Oral	23	12.4	12.4
Anti-Thymocyte Globulin (Rabbit)	7	11.7	11.7
Doxorubicin	72	11.3	11.3
Lamivudine	25	11.0	11.0
Mercaptopurine	14	10.9	10.9
Cytarabine	47	10.8	10.8
Obinutuzumab	13	10.7	10.7
Entecavir	9	10.4	10.4
Valganciclovir	14	10.1	10.1
Valganciclovir Hydrochloride	14	10.1	10.1
Valganciclovir Hydrochloride Powder,	9	10.0	10.0
Etoposide	49	9.2	9.2
Amphotericin B	8	8.6	8.6
Ibrutinib	46	7.9	7.9
Daratumumab	23	7.8	7.8
Carfilzomib	16	7.7	7.7
Vincristine Sulfate	16	7.4	7.4
Thiotepa	5	7.1	7.1
Bleomycin Sulfate	5	6.5	6.5
Bortezomib	38	5.8	5.8
Inclisiran	3	5.0	5.0
Ofatumumab	9	3.7	3.7
Alirocumab	6	3.2	3.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.